Literature DB >> 24891492

Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy.

Samantha C Lee1, John Feenstra2, Paul R Georghiou3.   

Abstract

Ruxolitinib is a novel inhibitor of the Janus kinase (JAK) pathway that has become available for the treatment of myelofibrosis. There are increasing reports of opportunistic infections associated with ruxolitinib therapy. We present a case of Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy. Clinicians should consider the use of pneumocystis prophylaxis when using ruxolitinib. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24891492      PMCID： PMC4054251          DOI： 10.1136/bcr-2014-204950

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  9 in total

1.  Progressive multifocal leukoencephalopathy associated with ruxolitinib.

Authors:  Rowan Wathes; Simon Moule; Dragana Milojkovic
Journal:  N Engl J Med       Date:  2013-07-11       Impact factor: 91.245

2.  Bilateral toxoplasmosis retinitis associated with ruxolitinib.

Authors:  Roger A Goldberg; Elias Reichel; Lauren J Oshry
Journal:  N Engl J Med       Date:  2013-08-15       Impact factor: 91.245

3.  Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis.

Authors:  G Caocci; F Murgia; L Podda; A Solinas; S Atzeni; G La Nasa
Journal:  Leukemia       Date:  2013-08-09       Impact factor: 11.528

4.  Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib.

Authors:  M Massa; V Rosti; R Campanelli; G Fois; G Barosi
Journal:  Leukemia       Date:  2013-10-22       Impact factor: 11.528

5.  Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment.

Authors:  Lana X Tong; Julie Jackson; Justin Kerstetter; Scott D Worswick
Journal:  J Am Acad Dermatol       Date:  2014-03       Impact factor: 11.527

6.  The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo.

Authors:  Annkristin Heine; Stefanie Andrea Erika Held; Solveig Nora Daecke; Stephanie Wallner; Sowmya Parampalli Yajnanarayana; Christian Kurts; Dominik Wolf; Peter Brossart
Journal:  Blood       Date:  2013-06-14       Impact factor: 22.113

Review 7.  Ruxolitinib: a new treatment option for myelofibrosis.

Authors:  Alex Ganetsky
Journal:  Pharmacotherapy       Date:  2013-01       Impact factor: 4.705

8.  An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.

Authors:  Nicholas G Wysham; Donald R Sullivan; Gopal Allada
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

9.  Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report.

Authors:  Claudia Colomba; Raffaella Rubino; Lucia Siracusa; Francesco Lalicata; Marcello Trizzino; Lucina Titone; Manlio Tolomeo
Journal:  BMC Res Notes       Date:  2012-10-05
  9 in total
  19 in total

Review 1.  Immunological Consequences of JAK Inhibition: Friend or Foe?

Authors:  Donal P McLornan; Alesia A Khan; Claire N Harrison
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

2.  Hyperlactatemia in diabetic ketoacidosis is common and can be prolonged: lactate time-series from 25 intensive care admissions.

Authors:  Thomas J Morgan; Peter H Scott; Christopher M Anstey; Francis G Bowling
Journal:  J Clin Monit Comput       Date:  2020-05-20       Impact factor: 2.502

3.  Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis.

Authors:  Norio Komatsu; Keita Kirito; Kazuya Shimoda; Takayuki Ishikawa; Kohshi Ohishi; Kazuma Ohyashiki; Naoto Takahashi; Hikaru Okada; Taro Amagasaki; Toshio Yonezu; Koichi Akashi
Journal:  Int J Hematol       Date:  2016-11-10       Impact factor: 2.490

Review 4.  Clinical potential of pacritinib in the treatment of myelofibrosis.

Authors:  Ana B Duenas-Perez; Adam J Mead
Journal:  Ther Adv Hematol       Date:  2015-08

Review 5.  Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.

Authors:  Cecilia Arana Yi; Constantine S Tam; Srdan Verstovsek
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

6.  Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors.

Authors:  Marissa A Zarakas; Jigar V Desai; Georgios Chamilos; Michail S Lionakis
Journal:  Curr Fungal Infect Rep       Date:  2019-07-05

7.  Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib.

Authors:  Róbert Pálmason; Ola Lindén; Johan Richter
Journal:  BMC Hematol       Date:  2015-07-11

Review 8.  Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.

Authors:  A Yacoub; O Odenike; S Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

Review 9.  Definition and management of ruxolitinib treatment failure in myelofibrosis.

Authors:  A Pardanani; A Tefferi
Journal:  Blood Cancer J       Date:  2014-12-12       Impact factor: 11.037

Review 10.  Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis.

Authors:  Giovanni Barosi; Vittorio Rosti; Robert Peter Gale
Journal:  Onco Targets Ther       Date:  2015-05-18       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.